基础医学与临床 ›› 2022, Vol. 42 ›› Issue (6): 864-870.doi: 10.16352/j.issn.1001-6325.2022.06.026

• 研究论文 • 上一篇    下一篇

肝细胞癌中EZH2基因相关的表观遗传调控机制

赵钰珊, 冀梦蝶, 董昱诚, 郭鑫, 宋博渊, 陈阳*   

  1. 中国医学科学院基础医学研究所 北京协和医学院基础学院 生物化学与分子生物学系医学分子生物学国家重点实验室, 北京 100005
  • 收稿日期:2022-03-25 修回日期:2022-04-22 出版日期:2022-06-05 发布日期:2022-06-02
  • 通讯作者: * yc@ibms.pumc.edu.cn
  • 基金资助:
    国家自然科学基金(31871343)

Epigenetic regulation mechanism of EZH2 gene in hepatocellular carcinoma

ZHAO Yu-shan, JI Meng-die, DONG Yu-cheng, GUO Xin, SONG Bo-yuan, CHEN Yang*   

  1. State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences CAMS, School of Basic Medicine PUMC, Beijing 100005, China
  • Received:2022-03-25 Revised:2022-04-22 Online:2022-06-05 Published:2022-06-02
  • Contact: * yc@ibms.pumc.edu.cn

摘要: 目的 结合肝细胞癌公共数据分析与生物实验,初步探索肝细胞癌中EZH2基因的表观遗传调控机制。方法 使用TCGA公共数据分析EZH2基因表达与肝细胞癌进展和预后之间的关系。随后,使用ATP细胞活性检测法、结晶紫法分析EZH2抑制剂GSK343对肝细胞癌细胞系HepG2细胞活性和增殖的影响。之后,分析TCGA公共数据样本中EZH2高表达组和低表达组之间的差异表达基因。其后,使用ENCODE中的ChIP-seq公共数据分析EZH2下游靶基因转录起始位点上的组蛋白修饰特征。最后,用RT-qPCR检测受到EZH2调控的下游靶基因的基因表达。 结果 EZH2基因表达与肝细胞癌1~3期的病程进展显著相关(P<0.05);生存分析表明EZH2基因高表达与肝细胞癌预后不良显著相关 (P<0.05);EZH2抑制剂能够显著抑制肝细胞癌细胞系HepG2的体外细胞活力和增殖能力(P<0.05);EZH2结合的基因转录起始位点上富集组蛋白修饰H3K27me3;163个基因在其转录起始位点附近存在EZH2结合信号,同时这些基因也在EZH2高表达组和低表达组之间显著差异表达;实验验证ADRA1A是EZH2的下游靶基因。结论 在肝细胞癌中EZH2基因可以通过表观遗传调控影响其下游靶基因的表达。

关键词: 肝细胞癌, zeste同源蛋白2增强子, 表观遗传调控

Abstract: Objective This study combined public data analysis with biological experiment using the tissues of hepato-cellular carcinoma to explore the epigenetic regulation mechanism of EZH2 gene which is potentially related to the progression of hepato-cellular carcinoma. Methods Using the TCGA's public clinical data of hepato-cellular carcinoma, the relation of EZH2 gene expression with tumor progression as well as prognosis was analyzed. Subsequently, the effect of EZH2 inhibitor GSK343(10 μmol/L) on the proliferation of hepato-cellular carcinoma cell line HepG2 was further analyzed by ATP cell activity assay and crystal violet assay. Then, the differentially expressed genes between EZH2 high expression group and low expression group in TCGA samples were analyzed. After that, the ChIP-seq public data of ENCODE was used to analyze the histone modification at the transcription starting site of EZH2 downstream target gene. Finally, RT-qPCR was used to detect the gene expression of downstream target genes regulated by EZH2. Results EZH2 gene-expression was significantly correlated with the progression of hepato-cellular carcinoma from stage 1 to stage 3(P<0.05). Survival analysis showed that the high expression of EZH2 gene was significantly correlated with the poor prognosis of hepatocellular carcinoma(P<0.05). The EZH2 inhibitor could significantly inhibit the proliferation of hepatocellular carcinoma cell line HepG2 in vitro (P<0.05). Histone modification H3K27me3 was enriched at the transcription start site of EZH2 binding gene. There was 163 genes significantly different in EZH2 high expression group and low expression group and had EZH2 binding sites at their transcription start sites. The experiment verified that ADRA1A was a downstream target gene of EZH2. Conclusions EZH2 gene may affect expression of its downstream target genes through epigenetic regulation in hepato-cellular carcinoma.

Key words: hepatocellular carcinoma, enhancer of zeste homolog 2, epigenetic regulation

中图分类号: